Mr. Rosenman has been our Chief Financial Officer since 2014. Prior to joining us, Mr. Rosenman was managing director and chief financial officer of Vivus, Inc., a biopharmaceutical company, from 2009 to 2014. Before that, he held various positions with Achaogen Inc., a private biopharmaceutical company, and served as the Chief Financial Officer of Denali Therapeutics Inc., a biopharmaceutical company, from its inception. Mr. Rosenman also has served as a director of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, from 2017 to 2021, when the company was acquired by PerkinElmer; Vivus, Inc., a biopharmaceutical company, from 2013 to 2021; as well as Medistem, Inc., a stem cell therapy company, ARYx Therapeutics Inc., a private drug discovery and development company, Infinity Pharmaceuticals, Inc., a drug discovery and development company, and a number of privately held companies. Mr. Rosenman holds a B.B.A. in Accounting and Finance from Pace University and an M.B.A. in Finance from the Wharton School of the University of Pennsylvania. Our board of directors believes that Mr. Rosenman is qualified to serve as a director based on his experience as our chief financial officer, his experience in the biopharmaceutical industry and his experience serving on the boards of directors of other companies. Mr. Rosenman currently serves as the chair of our audit committee and also serves on our human capital committee.